The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Polymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria
Abstract
BACKGROUND: Polymyxin B sulfate and colistin, also known as colistimethate, have not been used for many years because less toxic antimicrobials are available. Gram-negative bacteria that are resistant to the aminoglycosides, β-lactams, and fluoroquinolones are becoming more common. These bacteria are often susceptible to the polymyxins. OBJECTIVE: To present a review of the chemistry, antibacterial spectrum, dosing, pharmacokinetics, toxicity, and indications for polymyxin B sulfate and colistin. DATA SOURCE: A MEDLINE search (1966–1998) of the English-language literature was performed to identify primary literature on the polymyxins. Older citations (1949–1965) were identified through the bibliographies of these articles. STUDY SELECTION: All available reports of in vitro antibacterial activity, animal and clinical trials, and case reports were reviewed. DATA SYNTHESIS: The polymyxins are amphipathic molecules that interact with lipopolysaccharide in the bacterial outer membrane. They have potent antiendotoxic properties and antibacterial activity against Pseudomonas aeruginosa and many of the Enterobacteriaceae. Polymyxin B and colistin are usually given at a dose of 1.5–2.5 and 5 mg/kg/d, respectively, in two divided doses. Dosing must be altered in renal failure since the kidney is the primary route of elimination. Distribution into pleural fluid, joints, and cerebrospinal fluid is poor. Toxic effects involve the kidney and central nervous system. The polymyxins are recommended for serious systemic infections caused by gram-negative bacteria that are resistant to other agents. CONCLUSIONS: Polymyxin B sulfate and colistin have a role in the therapy of multidrug-resistant gram-negative bacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides
Morrison, D. C., & Jacobs, D. M. (1976) · Immunochemistry · doi:10.1016/0019-2791(76)90181-6 · Cited by 819
Polymyxin and Related Peptide Antibiotics
Storm, D. R., Rosenthal, K. S., & Swanson, P. E. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.003451 · Cited by 759
THE BARRIER FUNCTION OF THE GRAM‐NEGATIVE ENVELOPE
Leive, L. (1974) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1974.tb43261.x · Cited by 510
Archibald, L., Phillips, L., Monnet, D., McGowan, J. E., Tenover, F., & Gaynes, R. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.211 · Cited by 436
Interaction of divalent cations and polymyxin B with lipopolysaccharide
Schindler, M., & Osborn, M. J. (1979) · Biochemistry · doi:10.1021/bi00587a024 · Cited by 334
Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane
Hancock, R. E., & Wong, P. G. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.1.48 · Cited by 282
Aerosol Polymyxin and Pneumonia in Seriously Ill Patients
Feeley, T. W., du Moulin, G. C., Hedley-Whyte, J., Bushnell, L. S., Gilbert, J. P., & Feingold, D. S. (1975) · New England Journal of Medicine · doi:10.1056/nejm197509042931003 · Cited by 261
Nicas, T. I., & Hancock, R. E. W. (1980) · Journal of Bacteriology · doi:10.1128/jb.143.2.872-878.1980 · Cited by 221
Vaara, M., Vaara, T., Jensen, M., Helander, I., Nurminen, M., Rietschel, E. T., & Mäkelä, P. H. (1981) · FEBS Letters · doi:10.1016/0014-5793(81)80777-6 · Cited by 195
Electron microscopic studies on mode of action of polymyxin
Koike, M., Iida, K., & Matsuo, T. (1969) · Journal of Bacteriology · doi:10.1128/jb.97.1.448-452.1969 · Cited by 172
Cited by
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Antibacterial peptides for therapeutic use: obstacles and realistic outlook
MARR, A., GOODERHAM, W., & HANCOCK, R. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.04.006 · Cited by 1,051
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm357 · Cited by 834
Moffatt, J. H., Harper, M., Harrison, P., Hale, J. D. F., Vinogradov, E., Seemann, T., Henry, R., Crane, B., St. Michael, F., Cox, A. D., et al. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00834-10 · Cited by 812
Ciprofloxacin Causes Persister Formation by Inducing the TisB toxin in Escherichia coli
Dörr, T., Vulić, M., & Lewis, K. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000317 · Cited by 782
Structure−Activity Relationships of Polymyxin Antibiotics
Velkov, T., Thompson, P. E., Nation, R. L., & Li, J. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900999h · Cited by 780
Colistin: an update on the antibiotic of the 21st century
Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M., & Rolain, J.-M. (2012) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.12.78 · Cited by 581
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Landman, D., Georgescu, C., Martin, D. A., & Quale, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00006-08 · Cited by 565
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Polymyxin: Alternative Mechanisms of Action and Resistance
Trimble, M. J., Mlynárčik, P., Kolář, M., & Hancock, R. E. W. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025288 · Cited by 454
Nation, R. L., & Li, J. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328332e672 · Cited by 443
Rescuing the Last-Line Polymyxins: Achievements and Challenges
Nang, S. C., Azad, M. A. K., Velkov, T., Zhou, Q. (., & Li, J. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000020 · Cited by 421
Nano-drug delivery systems in wound treatment and skin regeneration
Wang, W., Lu, K.-J., Yu, C.-H., Huang, Q.-L., & Du, Y.-Z. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-019-0514-y · Cited by 411
Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa
Rossolini, G. M., & Mantengoli, E. (2005) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01161.x · Cited by 395
Gales, A. C., Reis, A. O., & Jones, R. N. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.183-190.2001 · Cited by 382
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-06 · Cited by 366
Branski, L. K., Al-Mousawi, A., Rivero, H., Jeschke, M. G., Sanford, A. P., & Herndon, D. N. (2009) · Surgical Infections · doi:10.1089/sur.2009.024 · Cited by 365
Obritsch, M. D., Fish, D. N., MacLaren, R., & Jung, R. (2005) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.2005.25.10.1353 · Cited by 342
Gales, A. C., Jones, R. N., Turnidge, J., Rennie, R., & Ramphal, R. (2001) · Clinical Infectious Diseases · doi:10.1086/320186 · Cited by 309
Antimicrobial Peptides: Current Status and Therapeutic Potential
Koczulla, A. R., & Bals, R. (2003) · Drugs · doi:10.2165/00003495-200363040-00005 · Cited by 306
Gales, A. C., Jones, R. N., & Sader, H. S. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01351.x · Cited by 302
History of antimicrobial drug discovery: Major classes and health impact
Aminov, R. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.10.001 · Cited by 296
Rotstein, C., Evans, G., Born, A., Grossman, R., Light, R. B., Magder, S., McTaggart, B., Weiss, K., & Zhanel, G. G. (2008) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2008/593289 · Cited by 282
Role of oxidative stress in persister tolerance
Wu, Y., Vulić, M., Keren, I., & Lewis, K. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00921-12 · Cited by 276
Markou, N., Apostolakos, H., Koumoudiou, C., Athanasiou, M., Koutsoukou, A., Alamanos, I., & Gregorakos, L. (2003) · Critical Care · doi:10.1186/cc2358 · Cited by 278
Pneumonia Due to Pseudomonas aeruginosa
Fujitani, S., Sun, H.-Y., Yu, V. L., & Weingarten, J. A. (2011) · Chest · doi:10.1378/chest.10-0166 · Cited by 273
Current Update on Intrinsic and Acquired Colistin Resistance Mechanisms in Bacteria
Gogry, F. A., Siddiqui, M. T., Sultan, I., & Haq, Q. M. R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.677720 · Cited by 265
Lo-Ten-Foe, J. R., de Smet, A. M. G. A., Diederen, B. M. W., Kluytmans, J. A. J. W., & van Keulen, P. H. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01406-06 · Cited by 242
Metadata
- Authors
- Evans, M. E., Feola, D. J., & Rapp, R. P.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 1999-09
- Volume
- 33
- Issue
- 9
- Pages
- 960-967
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2162745520
- Cited by
- 544
- References
- 43
- FWCI
- 4.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.